EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Robot-assisted radical cystectomy: Where we are in 2023

Jang Hee Han iD, Ja Hyeon Ku iD

Investigative and Clinical Urology · 2023

DOI: 10.4111/icu.20220384 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Investigative and Clinical Urology, 2023. Verfasst von Jang Hee Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Cystectomy, Robotics. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Open radical cystectomy (ORC) is associated with high rates of perioperative morbidity and mortality, owing to its extensive surgical nature and the high frequency of multiple co-morbidities among patients. As an alternative, robot-assisted radical cystectomy (RARC) has been increasingly adopted worldwide, being a reliable treatment option that utilizes minimally invasive surgery. Seventeen years have passed since the advent of the RARC, and comprehensive long-term follow-up data are now becoming available. The present review focuses on the current knowledge of RARC in 2023, and analyzes various aspects, including oncological outcomes, peri/post-operative complications, post-operative quality of life (QoL) change, and cost-effectiveness. Oncologically, RARC showed comparable oncological outcomes to ORC. With regard to complications, RARC was associated with lower estimated blood loss, lower intraoperative transfusion rates, shorter length of stay, lower risk of Clavien-Dindo grade III-V complications, and lower 90-day rehospitalization rates than ORC. In particular, RARC with intracorporeal urinary diversion (ICUD) performed by high-volume centers significantly reduced the risk of post-operative major complications. In terms of post-operative QoL, RARC with extracorporeal urinary diversion (ECUD) showed comparable results to ORC, while RARC with ICUD was superior in some respects. As the RARC implementation rate increases and the learning curve is overcome, more prospective studies and randomized controlled trials with large-scale patients are expected to be conducted in the future. Accordingly, sub-group analysis in various groups such as ECUD, ICUD, continent and non-continent urinary diversion, etc. is considered to be possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystectomyRoboticsHumansQuality of LifeProspective StudiesLearning CurvePostoperative ComplicationsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

CystectomyPostoperative complicationsQuality of lifeRoboticsTreatment outcome

Autor:innen und Institutionen

  • Department of Urology, Seoul National University Hospital, Seoul, Korea.
  • Department of Urology, Seoul National University College of Medicine, Seoul, Korea. kuuro70@snu.ac.kr.

ORCID-Profile: Jang Hee Han, Ja Hyeon Ku

Zitieren

APA

Han, J. H., & Ku, J. H. (2023). Robot-assisted radical cystectomy: Where we are in 2023. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20220384

Vancouver

Han JH, Ku JH. Robot-assisted radical cystectomy: Where we are in 2023. Investigative and Clinical Urology. 2023. doi:10.4111/icu.20220384

BibTeX
@article{Han2023,
  author = {Han, Jang Hee and Ku, Ja Hyeon},
  title = {Robot-assisted radical cystectomy: Where we are in 2023},
  journal = {Investigative and Clinical Urology},
  year = {2023},
  doi = {10.4111/icu.20220384}
}
Kostenlos starten →